Post-hoc analysis of Xultophy (insulin degludec/liraglutide) shows drug reduces risk factors for cardiovascular disease in patients with type 2 diabetes.- Novo Nordisk.
According to a new post-hoc analysis, in people with type 2 diabetes, Xultophy (insulin degludec/liraglutide), from Novo Nordisk, significantly reduced a number of risk factors associated with an increased risk of cardiovascular disease (CVD) compared to basal insulin. People treated with Xultophy had significantly lower systolic blood pressure, lower total cholesterol as well as lower low-density lipoprotein cholesterol (so-called 'bad cholesterol'), and significant weight changes in favour of Xultophy compared to people treated with basal insulin (insulin glargine U100 or insulin degludec). A small but statistically significant increase in heart rate was also observed with Xultophy.
The CV risk markers data came from a new post-hoc analysis of two Xultophy randomised-controlled clinical trials, comparing the efficacy and safety of Xultophy against insulin degludec in DUAL II and against insulin glargine U100 in DUAL V, both with metformin for 26 weeks. Data were presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD 2017).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins